Cero Therapeutics (CERO) grants 1.61M stock options to Chief Development Officer

Rhea-AI Filing Summary

Cero Therapeutics Holdings, Inc. reported that Chief Development Officer Kristen Pierce received a grant of stock options on 01/07/2026. The award covers 1,612,099 stock options, each representing the right to buy one share of common stock at an exercise price of $0.055 per share. Following this grant, Pierce beneficially owns 1,612,099 derivative securities, all held in direct ownership form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pierce Kristen

(Last) (First) (Middle)

CERO THERAPEUTICS HOLDINGS, INC.

201 HASKINS WAY, SUITE 230

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CERO THERAPEUTICS HOLDINGS, INC. [ CERO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.055	01/07/2026		A		1,612,099		01/07/2026	01/06/2036	Common Stock	1,612,099	$0.00	1,612,099	D

Explanation of Responses:

	/s/ Andrew Kucharchuk, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cero Therapeutics (CERO) report for Kristen Pierce?

Cero Therapeutics reported that Chief Development Officer Kristen Pierce was granted 1,612,099 stock options on 01/07/2026, coded as an A (grant) transaction.

What is the exercise price of the stock options granted to Kristen Pierce at Cero Therapeutics (CERO)?

The stock option grant to Kristen Pierce has a conversion or exercise price of $0.055 per underlying share of common stock.

How many Cero Therapeutics stock options does Kristen Pierce own after the latest grant?

After the reported transaction, Kristen Pierce beneficially owns 1,612,099 derivative securities (stock options) in direct ownership form.

When do Kristen Pierce’s Cero Therapeutics stock options become exercisable and when do they expire?

The stock options reported for Kristen Pierce are listed as exercisable on 01/07/2026 and have an expiration date of 01/06/2036.

What type of security was involved in the Cero Therapeutics (CERO) Form 4 filing?

The filing involves a Stock Option (Right to Buy) derivative security, tied to 1,612,099 shares of Cero Therapeutics common stock.

Is Kristen Pierce’s ownership in Cero Therapeutics reported as direct or indirect?

The Form 4 reports direct (D) ownership for the 1,612,099 stock options held by Kristen Pierce.